• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

抗瘤抑素 M 抗体抑制鳞状细胞癌中瘤抑素 M 受体过表达的促恶性作用。

Anti-oncostatin M antibody inhibits the pro-malignant effects of oncostatin M receptor overexpression in squamous cell carcinoma.

机构信息

Department of Pathology, University of Cambridge, Cambridge, UK.

Biodonostia Health Research Institute, San Sebastian, Spain.

出版信息

J Pathol. 2018 Mar;244(3):283-295. doi: 10.1002/path.5010. Epub 2018 Jan 9.

DOI:10.1002/path.5010
PMID:29205362
Abstract

The oncostatin M (OSM) receptor (OSMR) shows frequent gene copy number gains and overexpression in cervical squamous cell carcinomas (SCCs), associated with adverse clinical outcomes. In SCC cells that overexpress OSMR, the major ligand OSM induces multiple pro-malignant effects, including invasion, secretion of angiogenic factors, and metastasis. Here, we demonstrate, for the first time, that OSMR overexpression in SCC cells activates cell-autonomous feed-forward signalling, via further expression of OSMR and OSM and sustained STAT3 activation, despite expression of the negative regulator suppressor of cytokine signalling 3 (SOCS3). The pro-malignant effects associated with OSMR overexpression are critically mediated by JAK-STAT3 activation, which is induced by exogenous OSM and also by autocrine OSM-OSMR interactions. Importantly, specific inhibition of OSM-OSMR interactions by neutralizing antibodies significantly inhibits STAT3 activation and feed-forward signalling, leading to reduced invasion, angiogenesis, and metastasis. Our findings are supported by data from 1254 clinical SCC samples, in which OSMR levels correlated with multiple cognate genes, including OSM, STAT3, and downstream targets. These data strongly support the development of OSM-OSMR-blocking antibodies as biologically targeted therapies against SCCs of the cervix and other anatomical sites. Copyright © 2017 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.

摘要

肿瘤坏死因子配体超家族成员 11(骨保护素配体)(OPGL)是一种跨膜蛋白,属于肿瘤坏死因子配体超家族成员 11 家族,通过与核因子 κB 受体活化因子配体(RANKL)结合来激活破骨细胞前体细胞的分化和成熟,促进破骨细胞的形成和功能,从而导致骨吸收。

相似文献

1
Anti-oncostatin M antibody inhibits the pro-malignant effects of oncostatin M receptor overexpression in squamous cell carcinoma.抗瘤抑素 M 抗体抑制鳞状细胞癌中瘤抑素 M 受体过表达的促恶性作用。
J Pathol. 2018 Mar;244(3):283-295. doi: 10.1002/path.5010. Epub 2018 Jan 9.
2
Oncostatin M Receptor-Targeted Antibodies Suppress STAT3 Signaling and Inhibit Ovarian Cancer Growth.抑瘤素 M 受体靶向抗体抑制 STAT3 信号通路并抑制卵巢癌细胞生长。
Cancer Res. 2021 Oct 15;81(20):5336-5352. doi: 10.1158/0008-5472.CAN-21-0483. Epub 2021 Aug 11.
3
Overexpression of the oncostatin M receptor in cervical squamous cell carcinoma cells is associated with a pro-angiogenic phenotype and increased cell motility and invasiveness.在宫颈鳞状细胞癌细胞中过表达的骨桥蛋白受体与促血管生成表型以及增加的细胞迁移和侵袭性相关。
J Pathol. 2011 Nov;225(3):448-62. doi: 10.1002/path.2968. Epub 2011 Sep 26.
4
Oncostatin M receptor, positively regulated by SP1, promotes gastric cancer growth and metastasis upon treatment with Oncostatin M.受 SP1 正向调控的抑瘤素 M 受体促进了抑瘤素 M 治疗后的胃癌生长和转移。
Gastric Cancer. 2019 Sep;22(5):955-966. doi: 10.1007/s10120-019-00934-y. Epub 2019 Feb 18.
5
Overexpression of the oncostatin-M receptor in cervical squamous cell carcinoma is associated with epithelial-mesenchymal transition and poor overall survival.抑瘤素-M受体在宫颈鳞状细胞癌中的过表达与上皮-间质转化及总体生存率低相关。
Br J Cancer. 2016 Jul 12;115(2):212-22. doi: 10.1038/bjc.2016.199. Epub 2016 Jun 28.
6
Oncostatin M receptor is a novel therapeutic target in cervical squamous cell carcinoma.抑瘤素 M 受体是宫颈鳞癌的一个新的治疗靶点。
J Pathol. 2014 Mar;232(4):386-90. doi: 10.1002/path.4305.
7
The AB loop and D-helix in binding site III of human Oncostatin M (OSM) are required for OSM receptor activation.结合位点 III 中人类肿瘤坏死因子样弱诱导剂(OSM)的 AB 环和 D 螺旋对于 OSM 受体的激活是必需的。
J Biol Chem. 2018 May 4;293(18):7017-7029. doi: 10.1074/jbc.RA118.001920. Epub 2018 Mar 6.
8
Virus and Host Events in Squamous Carcinogenesis.鳞状细胞癌发生过程中的病毒与宿主事件
Keio J Med. 2016;65(4):78. doi: 10.2302/kjm.65-004-ABST.
9
Gain and overexpression of the oncostatin M receptor occur frequently in cervical squamous cell carcinoma and are associated with adverse clinical outcome.抑瘤素M受体的获得和过表达在宫颈鳞状细胞癌中频繁发生,并与不良临床结局相关。
J Pathol. 2007 Jul;212(3):325-34. doi: 10.1002/path.2184.
10
Murine Oncostatin M Acts via Leukemia Inhibitory Factor Receptor to Phosphorylate Signal Transducer and Activator of Transcription 3 (STAT3) but Not STAT1, an Effect That Protects Bone Mass.小鼠抑瘤素M通过白血病抑制因子受体作用使信号转导和转录激活因子3(STAT3)磷酸化,但不使STAT1磷酸化,该效应可保护骨量。
J Biol Chem. 2016 Oct 7;291(41):21703-21716. doi: 10.1074/jbc.M116.748483. Epub 2016 Aug 18.

引用本文的文献

1
Targeting the major pro-inflammatory interleukin-6-type cytokine receptor gp130 by antagonistic single domain antibodies.通过拮抗性单域抗体靶向主要促炎白细胞介素-6型细胞因子受体gp130。
Front Immunol. 2025 Aug 15;16:1613004. doi: 10.3389/fimmu.2025.1613004. eCollection 2025.
2
Drug Repurposing to Inhibit Oncostatin M in Crohn's Disease.药物再利用以抑制克罗恩病中的制瘤素M
Molecules. 2025 Apr 24;30(9):1897. doi: 10.3390/molecules30091897.
3
Toll-Like receptor 3-mediated interferon-β production is suppressed by oncostatin m and a broader epithelial-mesenchymal transition program.
Toll 样受体 3 介导体干扰素-β 的产生受抑瘤素 m 和更广泛的上皮-间充质转化程序的抑制。
Breast Cancer Res. 2024 Nov 26;26(1):167. doi: 10.1186/s13058-024-01918-2.
4
Expanding the repertoire of Antibody Drug Conjugate (ADC) targets with improved tumor selectivity and range of potent payloads through in-silico analysis.通过计算机分析,扩展抗体药物偶联物 (ADC) 靶点的范围,提高肿瘤选择性和有效载荷的范围。
PLoS One. 2024 Aug 26;19(8):e0308604. doi: 10.1371/journal.pone.0308604. eCollection 2024.
5
Role of Oncostatin M in Exercise-Induced Breast Cancer Prevention.抑瘤素M在运动诱导的乳腺癌预防中的作用。
Cancers (Basel). 2024 Jul 31;16(15):2716. doi: 10.3390/cancers16152716.
6
Oncostatin M: Dual Regulator of the Skeletal and Hematopoietic Systems.抑瘤素M:骨骼和造血系统的双重调节因子
Curr Osteoporos Rep. 2024 Feb;22(1):80-95. doi: 10.1007/s11914-023-00837-z. Epub 2024 Jan 10.
7
Oncostatin M Reduces Pathological Neovascularization in the Retina Through Müller Cell Activation.抑瘤素 M 通过激活 Müller 细胞减少视网膜病理性血管生成。
Invest Ophthalmol Vis Sci. 2024 Jan 2;65(1):22. doi: 10.1167/iovs.65.1.22.
8
New perspectives in cancer immunotherapy: targeting IL-6 cytokine family.癌症免疫治疗的新视角:靶向白细胞介素-6 细胞因子家族。
J Immunother Cancer. 2023 Nov;11(11). doi: 10.1136/jitc-2023-007530.
9
Oncostatin M, Serpins, and Oxidative Stress in Extracellular Matrix Remodeling and Arteriovenous Fistula Maturation.抑瘤素M、丝氨酸蛋白酶抑制剂与细胞外基质重塑及动静脉内瘘成熟中的氧化应激
Cardiol Cardiovasc Med. 2023;7(2):129-140. doi: 10.26502/fccm.92920318. Epub 2023 Apr 20.
10
Oncostatin-M and OSM-Receptor Feed-Forward Activation of MAPK Induces Separable Stem-like and Mesenchymal Programs.抑瘤素-M 和 OSM 受体正反馈激活 MAPK 诱导分离的干细胞样和间充质程序。
Mol Cancer Res. 2023 Sep 1;21(9):975-990. doi: 10.1158/1541-7786.MCR-22-0715.